SCHEMBL255270

SCHEMBL255270

COc1ccccc1C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.55
CA2 P00918 3/20 0.55
CA7 P43166 2/20 0.55
CA9 Q16790 2/20 0.55
CA12 O43570 1/20 0.55
CA4 P22748 1/20 0.55
CA14 Q9ULX7 1/20 0.55
ATM Q13315 1/20 0.49
MAOB P27338 1/20 0.49
AR P10275 4/20 0.46
PGR P06401 1/20 0.46
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
ADRA2B P18089 1/20 0.44
PTGS1 P23219 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.43
NFE2L2 Q16236 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30093322 1.00 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL22827 0.92 ATM (0.48) CA1CA2CA7CA9CA12
SCHEMBL28228661 0.86 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL18543499 0.82 CA1 (0.50) CA1CA2CA7CA9CA12
SCHEMBL14191201 0.82 CA1 (0.50) CA1CA2CA7CA9CA12
SCHEMBL4652907 0.82 CA1 (0.50) CA1CA2CA7CA9CA12
SCHEMBL29749364 0.80 AR (0.49) CA1CA2CA7CA9CA12
SCHEMBL10451316 0.80 AR (0.49) CA1CA2CA7CA9CA12
SCHEMBL9952870 0.80 AR (0.44) CA1CA2CA7CA9CA12
SCHEMBL16049413 0.80 AR (0.44) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197345-A1 SYNTHESIS OF DIGLYCOLAMIDES UNITED STATES DEPARTMENT OF ENERGY 2025-06-19 US claimed
US-20230084927-A1 GLUCOSE UPTAKE INHIBITORS AND USES THEREOF METABOMED LTD. (IL) 2023-03-16 US claimed
WO-2021095032-A1 GLUCOSE UPTAKE INHIBITORS AND USES THEREOF METABOMED LTD (IL) 2021-05-20 WO claimed
CN-109776324-A Homoallyltrifluoromethyl compound and preparation method thereof 南京工业大学 2019-05-21 CN claimed
CN-107011313-A Replace application of the cinnamamide derivative in anxiolytic drugs is prepared 天士力制药集团股份有限公司 2017-08-04 CN claimed
US-9334253-B2 Direct trifluoromethylations using trifluoromethane UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2016-05-10 US claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
US-20140066640-A1 DIRECT TRIFLUOROMETHYLATIONS USING TRIFLUOROMETHANE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2014-03-06 US claimed
WO-2012148772-A1 DIRECT TRIFLUOROMETHYLATIONS USING TRIFLUOROMETHANE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-11-01 WO claimed
CN-1258119-C Photo-resist composition containing photo-alkali-generator and photo-acid-generator HYUNDAI ELECTRONICS IND (KR) 2006-05-31 CN claimed
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 EP claimed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US claimed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 WO claimed
CN-1289069-A Photo-resist composition containing photo-alkali-generator and photo-acid-generator HYUNDAI ELECTRONICS IND (KR) 2001-03-28 CN claimed
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
US-20250197345-A1 SYNTHESIS OF DIGLYCOLAMIDES UNITED STATES DEPARTMENT OF ENERGY 2025-06-19 US disclosed
CN-118497778-A Process for electrochemical synthesis of trifluoromethyl substituted alkoxy benzene compound 浙江九洲药业股份有限公司 2024-08-16 CN disclosed
US-4029651-A ESTERIFICATION ELI LILLY AND COMPANY (US) 1977-06-14 US disclosed
US-4008230-A Process for preparing 3-hydroxy cephalosporins ELI LILLY AND COMPANY (US) 1977-02-15 US disclosed
US-4008231-A Preparation of 3-methoxymethylcephalosporins ELI LILLY AND COMPANY (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP CA1 192/4885CA2 528/4885CA7 1176/4885
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT CA1 3301/4885CA2 1488/4885CA7 1931/4885
US-20140066640-A1 DIRECT TRIFLUOROMETHYLATIONS USING TRIFLUOROMETHANE TST, FLI1, CYP2F1 CA1 1170/4885CA2 898/4885CA7 154/4885
US-20250197345-A1 SYNTHESIS OF DIGLYCOLAMIDES RPN2, FUT6, RPN1 CA1 328/4885CA2 1303/4885CA7 124/4885
US-20230084927-A1 GLUCOSE UPTAKE INHIBITORS AND USES THEREOF SLC2A4, SLC2A1, SLC2A2 CA1 738/4885CA2 554/4885CA7 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.